|Bid||32.62 x 800|
|Ask||32.78 x 3000|
|Day's range||31.60 - 33.94|
|52-week range||30.25 - 83.99|
|Beta (5Y monthly)||1.74|
|PE ratio (TTM)||137.46|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
The FDA placed a hold on the company's planned clinical trial of an experimental Alzheimer's disease drug.
Denali (DNLI) announces wider-than-expected loss per share for third-quarter 2021. Nonetheless, its shares rise following the announcement.
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -35.29% and -78.45%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?